other names
{{ Info.Overview }}
Revenue {{ Info.Revenue | formatUSD }}
Headquarters {{ Info.Headquarters }}

Adviser Profile

As of Date 03/28/2024
Adviser Type - Large advisory firm
Number of Employees 7 -22.22%
of those in investment advisory functions 5
Registration SEC, Approved, 6/11/2020
Other registrations (1)
AUM* 565,157,554 50.68%
of that, discretionary 565,157,554 50.68%
Private Fund GAV* 473,138,924 133.89%
Avg Account Size 113,031,511 50.68%
SMA’s No
Private Funds 1
Contact Info 214 xxxxxxx
Websites

Client Types

- Pooled investment vehicles

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Recent News

Reported AUM

Discretionary
Non-discretionary
846M 725M 604M 483M 362M 242M 121M
2020 2021 2022 2023

Private Funds



Employees

Private Funds Structure

Fund Type Count GAV
Fund TypeHedge Fund Count1 GAV$473,138,924

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM #Funds
Adviser LEPERCQ DE NEUFLIZE ASSET MANAGEMENT LLC Hedge Fund475.3m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV475.3m AUM524.6m #Funds1
Adviser TRADELINK CAPITAL LLC Hedge Fund340.3m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV340.3m AUM330.2m #Funds2
Adviser LUMINA FUND MANAGEMENT LLC Hedge Fund- Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV- AUM7.0m #Funds-
Adviser KALEIDOSCOPE CAPITAL Hedge Fund455.7m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV455.7m AUM435.7m #Funds3
Adviser KRENSAVAGE ASSET MANAGEMENT, LLC Hedge Fund310.7m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV310.7m AUM310.7m #Funds2
Adviser BURKEHILL GLOBAL MANAGEMENT, LP Hedge Fund1.6b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV1.6b AUM1.2b #Funds5
Adviser OBRIEN GREENE & CO INC Hedge Fund14.6m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV14.6m AUM391.5m #Funds1
Adviser P/E GLOBAL LLC Hedge Fund702.3m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV702.3m AUM702.3m #Funds1
Adviser PL CAPITAL ADVISORS, LLC Hedge Fund304.9m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV304.9m AUM304.9m #Funds4
Adviser CALIXTO GLOBAL INVESTORS, LP Hedge Fund361.6m Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV361.6m AUM488.8m #Funds1

Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
Stck Ticker803607100 Stock NameSAREPTA THERAPEUTICS INC $ Position$32,170,696 % Position6.00% $ Change63.00% # Change34.00%
Stck Ticker02043Q107 Stock NameALNYLAM PHARMACEUTICALS INC (CALL) $ Position$36,450,000 % Position6.00% $ Change102.00% # Change-99.00%
Stck Ticker02043Q107 Stock NameALNYLAM PHARMACEUTICALS INC (PUT) $ Position$36,450,000 % Position6.00% $ Change78.00% # Change-99.00%
Stck Ticker22663K107 Stock NameCRINETICS PHARMACEUTICALS IN $ Position$26,373,158 % Position5.00% $ Change-12.00% # Change-9.00%
Stck Ticker87650L103 Stock NameTARSUS PHARMACEUTICALS INC $ Position$21,751,529 % Position4.00% $ Change-16.00% # Change13.00%
Stck Ticker834203309 Stock NameSOLENO THERAPEUTICS INC $ Position$18,174,401 % Position3.00% $ Change-25.00% # Change-21.00%
Stck Ticker803607100 Stock NameSAREPTA THERAPEUTICS INC (CALL) $ Position$15,800,000 % Position3.00% $ Change5.00% # Change-99.00%
Stck Ticker74006W207 Stock NamePRAXIS PRECISION MEDICINES I (PUT) $ Position$13,338,600 % Position2.00% $ Change # Change
Stck Ticker64125C109 Stock NameNEUROCRINE BIOSCIENCES INC (CALL) $ Position$13,767,000 % Position2.00% $ Change # Change
Stck Ticker670703107 Stock NameNUVALENT INC $ Position$11,500,452 % Position2.00% $ Change51.00% # Change49.00%

Brochure Summary

Overview

A. Advisory Firm Description. The Adviser is a Delaware limited liability company and has its principal place of business in Dallas, Texas. The Adviser was formed in 2015 by its founders, Neil Shahrestani and Chart Westcott. Vikram Khanna joined the Adviser prior to the launch of its business and is also considered a co-founder. Chart Westcott retired from his managerial positions at the Adviser in 2022, but the principal owners continue to be (directly or indirectly) Neil Shahrestani and Chart Westcott. B. Advisory Services Offered. The Adviser provides discretionary investment advisory services to clients structured as (i) private investment funds comprised of sophisticated, qualified investors, including but not limited to, high net worth individuals, pension plans, funds of funds, family offices, endowments and other institutions (each, a “Fund” and together, the “Funds”); and (ii) separately managed accounts generally organized for the benefit of private investment funds for which the Adviser acts as a sub-adviser, but that may also be beneficially owned directly by high net worth individuals, retirement plans, trusts, partnerships, corporations or other institutions (each, a “Separate Account” and together, the “Separate Accounts” and, collectively with the Funds, the “Clients”). The Funds are generally organized in a master- feeder structure in which the master fund is a Cayman Islands exempted limited partnership, and the feeder funds include a U.S.-domiciled feeder fund organized as a Delaware limited partnership and a non-U.S. domiciled feeder fund organized as a Cayman Islands exempted company. The feeder funds invest all or substantially all of their assets in, and conduct their investment activities indirectly through, the master fund. See Item 7 “Types of Clients” of this Brochure for additional discussion on types of Clients and investors therein. The Adviser seeks to generate consistently high, risk-adjusted returns for its Clients that are uncorrelated to the broader market. The Adviser seeks to achieve this objective primarily through employing a fundamental
approach to identify investment opportunities across the biotechnology and pharmaceutical sub-sectors in an effort to construct a portfolio of high conviction ideas with asymmetric risk/reward payoffs. See Item 8 “Methods of Analysis, Investment Strategies and Risk of Loss” of this Brochure for additional information on the Adviser’s investment strategy. C. Tailored Advisory Services. While each of its Clients follows the general investment objective and strategy stated above, the Adviser provides specific advisory services with respect to each Client based on the particular investment objectives and strategies described in the applicable Client’s (i) confidential offering memorandum or separate account agreement (as applicable) and (ii) governing documents (referred to collectively as “Offering Documents”), and not in accordance with the individual objectives of any particular underlying investor or beneficial owner of a Client. The Offering Documents of the Funds generally contain no restrictions on investing in any type of security. However, the Offering Documents of the Separate Accounts generally do set forth certain specific investment guidelines and parameters that have included restrictions on investing in (or limiting exposure to) certain types of securities, which can result in disparate performance compared with other Clients employing a similar investment objective and strategy. D. Wrap Fee Arrangements. The Adviser does not participate in wrap fee agreements. E. Amount of Client Assets. As of December 31, 2023, the Adviser’s regulatory assets under management were $565,157,554.00 in discretionary assets and $0.00 in non-discretionary assets. All information is this Brochure with respect to the investment objective and strategy of any Client of the Adviser (or any other term applicable to a specific Client) is qualified in its entirety by reference to the Offering Documents of such Client. There can be no assurance that any Client will achieve its investment objective or that an investment in any Client will be profitable.